Corvus Pharmaceuticals, Inc.
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
About
CEO
Dr. Richard A. Miller M.D.
Employees
28
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
863 Mitten Road, Burlingame, CA 94010, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 5, 2025 | — | — | — | — |
| Mar 18, 2025 | — | — | — | — |
| Nov 13, 2024 | -0.11 | -0.60 | -0.49 | 445.45% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 4 | — | 5 |
| Average estimate | — | -0.12 | — | -0.46 |
| Low estimate | — | -0.13 | — | -0.56 |
| High estimate | — | -0.10 | — | -0.34 |
| Last year EPS | — | -0.12 | — | -0.92 |
[stock_revenue_estimate]
Growth estimates
Current qtr
14.290%
Next qtr. (Mar 2025)
2.080%
Current year
-64.640%
Next year (Dec 2025)
49.890%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 16.53M | 24.47M | 29.12M | 31.83M | 37.98M |
| Selling general and admin | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -23.41M | -32.57M | -38.63M | -43.76M | -48.85M |
| Non operating interest income | |||||
| Income | — | — | — | 540,000 | 2.18M |
| Expense | — | — | 15,000 | — | — |
| Other income expense | -5.21M | -9.40M | -4.60M | 37.23M | — |
| Pretax income | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M |
| Tax provision | — | — | — | — | — |
| Net income | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M |
| Basic EPS | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 |
| Diluted EPS | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 |
| Basic average shares | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M |
| Diluted average shares | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M |
| EBITDA | -23.26M | -32.22M | -38.17M | -43.13M | -48.11M |
| Net income from continuing op. | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 45.55M | 68.24M | 109.46M | 85.53M | 83.65M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 12.62M | 13.16M | 63.46M | 16.46M | 5.15M |
| Other short term investments | 14.53M | 29.14M | 5.99M | 27.80M | 72.83M |
| Accounts receivable | 26,000 | 588,000 | 507,000 | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 524,000 | 626,000 | 1.19M | 585,000 | 547,000 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 220,000 | 102,000 | 128,000 | 406,000 | 486,000 |
| Non current assets | |||||
| Properties | 3.83M | 4.89M | 5.67M | 4.12M | 4.72M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 171,000 | 142,000 | 142,000 | 142,000 | 142,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 2.08M | 2.08M | 2.08M | 2.08M | 2.08M |
| Accumulated depreciation | -4.70M | -4.55M | -4.25M | -3.79M | -3.16M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 16.12M | 21.88M | 34.27M | 37.23M | — |
| Other non current assets | 89,000 | 129,000 | 236,000 | 414,000 | 513,000 |
| Total liabilities | 6.87M | 12.13M | 12.29M | 13.38M | 12.54M |
| Current liabilities | |||||
| Accounts payable | 1.53M | 1.98M | 1.57M | 3.47M | 2.45M |
| Accrued expenses | 3.04M | 6.28M | 5.11M | 5.20M | 5.28M |
| Short term debt | 1.37M | 1.23M | 1.05M | 1.08M | 878,000 |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 684,000 | 1.11M | 1.85M | 2.23M | 1.62M |
| Other current liabilities | 245,000 | 158,000 | 121,000 | 180,000 | — |
| Non current liabilities | |||||
| Long term debt | — | 1.37M | 2.60M | 1.23M | 2.31M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 5,000 | 5,000 | 5,000 | 3,000 | 3,000 |
| Retained earnings | -334.72M | -307.69M | -266.38M | -223.14M | -217.15M |
| Other shareholders equity | -967,000 | -563,000 | 1.87M | 4,000 | 29,000 |
| Total shareholders equity | 38.68M | 56.12M | 97.16M | 72.15M | 71.11M |
| Additional paid in capital | 374.36M | 364.36M | 361.67M | 295.28M | 288.22M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Net Income | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M |
| Depreciation | 151,000 | 367,000 | 460,000 | 632,000 | 743,000 | 847,000 | 842,000 | 594,000 | 148,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 2.15M | 2.69M | 4.23M | 5.75M | 7.35M | 7.14M | 6.23M | 3.83M | 428,000 |
| Other Non-Cash Items | — | — | — | — | — | — | — | 4.48M | 17.64M |
| Accounts Receivable | 562,000 | -81,000 | -507,000 | — | — | — | — | — | — |
| Accounts Payable | -451,000 | 411,000 | -1.90M | 1.02M | 450,000 | -1.46M | 1.55M | 518,000 | 1.24M |
| Other Assets & Liabilities | -119,000 | 34,000 | -27,000 | -100,000 | -206,000 | 304,000 | -434,000 | -174,000 | 639,000 |
| Operating Cash Flow | -24.74M | -37.88M | -40.99M | 1.30M | -38.34M | -40.11M | -47.47M | -27.13M | -11.24M |
| Investing Activities | |||||||||
| Capital Expenditures | -34,000 | -247,000 | -5,000 | -76,000 | -25,000 | -355,000 | -266,000 | -2.20M | -1.75M |
| Net Intangibles | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -47.05M | -66.19M | -9.36M | -42.54M | -138.59M | -161.86M | -88.31M | -258.28M | -104.39M |
| Sale of Investments | 62.62M | 43.16M | 30.92M | 87.39M | 141.87M | 132.02M | 173.40M | 217.92M | 14.10M |
| Investing Cash Flow | 15.54M | -23.28M | 21.56M | 44.77M | 3.26M | -30.19M | 84.83M | -42.56M | -92.03M |
| Financing Activities | |||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | — | — | — | — | -729,000 |
| Financing Cash Flow | 7.84M | — | 60.94M | 1.22M | — | 64.88M | 711,000 | 71.35M | 94.84M |
| Other Cash Details | |||||||||
| End Cash Position | 12.62M | 13.16M | 63.46M | 16.46M | 5.15M | 39.20M | 45.11M | 5.05M | 4.11M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -23.97M | -27.29M | -36.72M | -34.85M | -37.35M | -41.34M | -46.48M | -30.06M | -13.08M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,581,761 | 8.64M | 2.46% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 767,019 | 4.19M | 1.19% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 278,274 | 1.52M | 0.43% |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | Sep 30, 2024 | 123,700 | 675,402 | 0.19% |
| iShares Micro Cap ETF | Nov 30, 2024 | 95,959 | 523,936 | 0.15% |
| Fidelity Total Market Index Fund | Nov 30, 2024 | 91,003 | 496,876 | 0.14% |
| iShares Core S&P Total U.S. Stock Market ETF | Nov 30, 2024 | 72,789 | 397,427 | 0.11% |
| Fidelity Series Total Market Index Fund | Nov 30, 2024 | 66,995 | 365,792 | 0.10% |
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 47,461 | 259,137 | 0.07% |
| Vanguard Institutional Index-Inst Total Stock Market Ind | Sep 30, 2024 | 29,109 | 158,935 | 0.05% |
Article
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET.
Feb 4, 2025
Article
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo
Jan 13, 2025
Article
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company's presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 am PT.
Jan 7, 2025
